The global breast cancer core needle biopsy market is witnessing significant growth, driven by rising breast cancer incidence, increasing awareness of early detection, and advancements in minimally invasive diagnostic technologies. Core needle biopsy (CNB) is a critical procedure that allows precise tissue sampling, enabling accurate diagnosis and staging of breast cancer while minimizing patient discomfort and recovery time compared to surgical biopsies.
As of 2025, the global breast cancer core needle biopsy market is estimated at approximately USD 320 million. Projections indicate that the market will grow to around USD 565 million by 2035, expanding at a robust compound annual growth rate (CAGR) of about 5.7% over the decade. The market is supported by the increasing prevalence of breast cancer worldwide, government screening programs, and the adoption of image-guided biopsy techniques.
Key Market Highlights (2025 Baseline)
Market Value (2025): ~ USD 320 million
Forecast Value (2035): ~ USD 565 million
Forecast CAGR (2025–2035): ~ 5.7%
Leading Biopsy Type: Automated Core Needle Biopsy (~ 62% share in 2025)
Dominant Imaging Guidance: Ultrasound-guided biopsy (~ 45% share in 2025)
Leading End-User Segment: Hospitals (~ 70% share in 2025)
Top Growth Regions: North America, Europe, and Asia-Pacific
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=11930
Growth Drivers & Market Momentum
Rising Breast Cancer Incidence
Globally, breast cancer remains the most common cancer among women. Increasing incidence rates, especially in developing countries, have heightened the demand for effective and minimally invasive diagnostic procedures. Core needle biopsy allows for early and accurate diagnosis, which is critical for improving patient survival rates and optimizing treatment plans.
Technological Advancements & Image-Guided Procedures
The adoption of image-guided biopsy techniques, including ultrasound, stereotactic, and MRI guidance, has enhanced the accuracy and safety of core needle biopsies. Automated and vacuum-assisted core needle biopsy devices provide consistent tissue sampling, reduce procedural errors, and improve patient comfort, fueling market growth.
Growing Awareness and Screening Programs
Government initiatives, awareness campaigns, and routine screening programs have significantly increased early breast cancer detection. Patients are increasingly opting for minimally invasive diagnostic options over traditional surgical biopsies, which drives the adoption of core needle biopsy procedures.
Preference for Minimally Invasive Procedures
Minimally invasive procedures are preferred due to shorter recovery times, reduced complications, and lower costs compared to surgical biopsies. Core needle biopsy offers the advantage of accurate diagnosis while avoiding the need for larger surgical interventions, making it the standard of care in many clinical settings.
Expansion of Healthcare Infrastructure in Emerging Markets
Healthcare infrastructure development in emerging economies, including better-equipped hospitals, growing diagnostic centers, and improved access to imaging technologies, is driving adoption of core needle biopsy procedures. These trends, coupled with increasing medical tourism, present significant market opportunities.
Challenges & Market Constraints
High Cost of Advanced Biopsy Devices: Automated and vacuum-assisted devices are more expensive than manual core needles, limiting adoption in cost-sensitive regions.
Limited Skilled Professionals: The accuracy of image-guided core needle biopsy depends on trained radiologists and pathologists, and a shortage of skilled personnel may constrain market growth.
Regulatory Hurdles: Medical devices must comply with stringent regulatory requirements, which can delay product approvals and market entry.
Competition from Alternative Diagnostic Methods: Emerging non-invasive imaging techniques and liquid biopsy technologies may serve as alternatives to traditional core needle biopsies, posing competitive challenges.
Strategic Recommendations
For Device Manufacturers
Focus on innovation by developing automated, vacuum-assisted, and ergonomically designed biopsy devices with high accuracy and ease of use.
Expand distribution networks in emerging markets to capitalize on increasing healthcare access and rising breast cancer awareness.
Offer training programs for healthcare professionals to enhance adoption and ensure proper device usage.
For Healthcare Providers
Invest in state-of-the-art imaging technologies to complement core needle biopsy procedures and improve diagnostic accuracy.
Promote awareness about minimally invasive biopsy procedures to patients, emphasizing reduced discomfort, shorter recovery, and diagnostic reliability.
For Investors & Market Entrants
Recognize core needle biopsy devices as a growing niche within the broader breast cancer diagnostics market.
Consider opportunities in emerging markets where rising cancer incidence and improving healthcare infrastructure present untapped potential.
Focus on innovative and cost-effective device solutions to cater to price-sensitive regions while maintaining clinical efficacy.
Market Outlook to 2035
By 2035, the global breast cancer core needle biopsy market is expected to reach approximately USD 565 million, driven by early detection initiatives, increasing breast cancer prevalence, and adoption of minimally invasive procedures. North America and Europe will remain significant markets due to advanced healthcare infrastructure, high awareness, and routine screening programs. Meanwhile, Asia-Pacific is expected to exhibit the fastest growth due to rising healthcare expenditure, expanding hospital networks, and growing awareness of breast cancer diagnostics.
Manufacturers and healthcare providers focusing on technological innovation, improved procedural accuracy, cost-effective solutions, and professional training are likely to gain a competitive edge. With growing emphasis on patient comfort, accurate diagnosis, and minimally invasive care, core needle biopsy procedures will continue to be a critical component in the global fight against breast cancer.
Have specific requirements or need assistance on report pricing or have a limited budget? Please contact [email protected]
About Fact.MR:
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
